Oric Pharmaceuticals, Inc. ORIC

On August 3, ORIC Pharmaceuticals (NASDAQ:ORIC) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once. The company started Himalayas-1, a global Phase 3 trial of its lead prostate cancer drug rinzimetostat, while holding $387.6 million in cash and investments to fund the effort. That […]

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the “Grant Date”), ORIC granted a total of 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who began their employment with ORIC in August 2026. These inducement gra

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference – Participating in a fireside chat on Wednesday, September 9, 2026, at 2:15 p.m. ET. Mana

In early August 2026, ORIC Pharmaceuticals reported second-quarter and first-half results showing a wider net loss of US$41.49 million and US$77.26 million respectively, but a narrower basic loss per share from continuing operations compared with a year earlier. Just days before, the company also filed a US$12.41 million shelf registration for 1,100,000 common shares under an ESOP-related offering, highlighting ongoing use of equity-based incentives alongside its loss-making operations. We...

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint

Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Phar

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the initiation of the Himala

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in post-abiraterone mCRPC supporting potential best-in-disease profile, including a highly differentiated safety profile and landmark rPFS consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC Reported early rinzimetostat data in po

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat pro

ORIC Pharmaceuticals (ORIC) updated investors on Phase 1b data for rinzimetostat plus darolutamide in metastatic castration resistant prostate cancer, and selected a 400 mg daily dose for a planned global Phase 3 trial. See our latest analysis for ORIC Pharmaceuticals. The latest rinzimetostat update comes after a sharp 1 day share price return of 18.93% to US$8.89, following a 27.07% 7 day share price decline. The 1 year total shareholder return of 93.68% points to strong but volatile...

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.

In late March 2026, ORIC Pharmaceuticals reported Phase 1b data showing that rinzimetostat 400 mg once daily plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer achieved strong early radiographic progression-free survival with mostly mild side effects, and selected this dose for the planned global Phase 3 Himalayas-1 trial. A key insight is that rinzimetostat’s exposure–response analysis suggested similar efficacy at 400 mg and 600 mg but meaningfully lower...